Figure 2: HCF prophylactic vaccination improved the survival in tumor-bearing mice. Survival of treated and control mice was followed for 100 days after tumor challenge. Mice were euthanized when subcutaneous tumors reached 20 mm or when mice became moribund. Tumor-free surviving mice () previously treated with HCF were rechallenged with CT26 cells at day 90. Representative results of one of 3 independent experiments are shown.